Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Cambio hacia las ganancias
El rendimiento de la empresa ha pasado a ser rentable. Sus ingresos netos anuales más recientes han sido de USD.
Sobrevalorada
El PE más reciente de la empresa es 24.52, en un rango percentil alto de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 52.51M acciones, lo que supone una reducción del 16.27% con respecto al trimestre anterior.
En posesión de Chuck Royce
El inversor estrella Chuck Royce posee 1.58M acciones de este valor.
Mayor actividad del mercado
La empresa está generando mayor interés entre los inversores, con una relación de rotación de 20 días del 0.66.